Synthesis and Structure–Activity Relationships for Extended Side Chain Analogues of the Antitubercular Drug (6S)-2-Nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824)-Reference-Cited by-同舟云学术

Synthesis and Structure–Activity Relationships for Extended Side Chain Analogues of the Antitubercular Drug (6S)-2-Nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824)

Published:2015-03-27 Issue:7 Volume:58 Page:3036-3059
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Palmer Brian D.¹,Sutherland Hamish S.¹,Blaser Adrian¹,Kmentova Iveta¹,Franzblau Scott G.²,Wan Baojie²,Wang Yuehong²,Ma Zhenkun³,Denny William A.¹,Thompson Andrew M.¹

Affiliation:

1. Auckland Cancer Society Research Centre, School of Medical Sciences, The University of Auckland, Private Bag 92019, Auckland 1142, New Zealand

2. Institute for Tuberculosis Research, College of Pharmacy, University of Illinois at Chicago, 833 South Wood Street, Chicago, Illinois 60612, United States

3. Global Alliance for TB Drug Development, 40 Wall Street, New York, New York 10005, United States

Funder

Global Alliance for TB Drug Development

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/jm501608q

Reference80 articles.

1. Global Tuberculosis Control: WHO Report 2011.World Health Organization:Geneva, Switzerland, 2011.

2. XDR-TB, What is it; How is it Treated; and why is Therapeutic Failure so High?